DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1575)

Indian Generics Manufacturers Penetrate U.S. Generics Market: Case Studies in Success and Failure and Near-Term Opportunities

The generics industry provides a notable bright spot amidst escalating U.S. healthcare costs, which are projected to hit $2.9 trillion in 2013 and reach $4.5 trillion by 2020. Generics have saved U.S. consumers an estimated $1 trillion over the last decade. Growth in the U.S. generics market will be driven by the loss of patent protection for a number of brands; between 2013 and 2020, over $155 billion in brand sales will lose patent protection.

While the leaders in the generics market include large U.S. and multinational players Teva Pharmaceutical Industries, Mylan, and Actavis, India-based companies have emerged as a growing competitive force in the U.S. generics landscape. In 2012, over 20% of the retail generic prescriptions dispensed were from Indian firms, and included the biggest prize of 2011: Ranbaxy Laboratories’ first-to-file rights for generic Lipitor (atorvastatin). This trend looks to continue for the near term as India leads in Type II drug master filings and in 2013, for the first time, India-based companies surpassed U.S. companies with the most ANDAs filed.

Despite their progress penetrating the U.S. generics market, Indian companies face a number of sizable challenges to remain competitive. Patent events will progressively shift from oral, small-molecule generics to more-complex formulations and biosimilars opportunities, which will require increased R&D spend and more-advanced manufacturing technologies. Perhaps most importantly, product quality has emerged as a new priority for success in the U.S. generics market, a topic that Indian companies know all too well from the recent lapses by Ranbaxy and others, and for which the FDA proclaimed was one of their “highest priorities” in 2013.

Questions Answered in This Report:

  • Growth in the U.S. generics industry will be driven by favorable healthcare policies as well as a number of brand loss of exclusivity events.  Between 2013 and 2020, over $155 billion in brand sales will lose U.S. patent protection; however, after 2014, interest will turn from oral small-molecule drugs to more-complex formulations and biologics.  What key brands will face patent expiration through 2020? Where are the peak years of opportunity for generics manufacturers, and what capabilities will manufacturers need to capitalize on these opportunities?

  • India is the largest provider of generic drugs globally, with generics exports representing 20% by volume. The key target market for pharma exports is the United States, and India’s aggressive growth targets in the pharmaceutical market will rely heavily on success in the U.S. market. Which leading India-based pharma companies have most successfully penetrated the U.S. generics market? Which companies are leading in Type II drug master filings and ANDA submissions?

  • In light of recent quality issues, product quality has emerged as a new priority for success in the U.S. generics market—most notably at India-based Ranbaxy. What can generics competitors learn from the hurdles Ranbaxy and other India-based generics companies have faced regarding manufacturing quality? How did market leader Teva rise to the top of the global generics industry, and what lessons can be learned from Teva’s success?


Markets covered: United States, India.